Avanir’s breath-powered migraine treatment a step closer to US approval?
This article was originally published in Clinica
Executive Summary
The US FDA has accepted for review the new drug application (NDA) for Avanir Pharmaceuticals' AVP-825, an investigational drug-device combination, as an acute treatment for migraines.